secwatch.observer — SEC 8-K summary
======================================

Issuer:     MACROGENICS INC (MGNX)
CIK:        0001125345
Form:       8-K
Filed at:   2026-07-23T20:07:30+00:00
Accession:  0001125345-26-000050
Event type: other_material
Sentiment:  positive
Materiality: 0.65
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MacroGenics MGC026 Phase 1 meets SCCHN Stage 1 threshold; ESMO poster accepted
------------------------------------------------------------------------------

- MGC026, a B7-H3-directed ADC, achieved pre-specified Stage 1 response threshold in SCCHN cohort; Stage 2 enrollment underway.
- Dose escalation completed; 7.5 mg/kg q3W selected for expansion in SCCHN, endometrial, melanoma, soft tissue sarcoma.
- As of July 8, 2026, 74 patients enrolled; no interstitial lung disease or ocular toxicity reported.
- Interim Phase 1 results accepted for poster at ESMO 2026 (Oct 23-27, Madrid); also lorigerlimab poster on gynecologic cancers.
- CEO Eric Risser: 'look forward to sharing data at ESMO.'

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000050/0001125345-26-000050-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1125345/000112534526000050/mgnx-20260723.htm
  HTML page:      https://secwatch.observer/filing/0001125345-26-000050

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer